世界の脆弱X症候群市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Fragile X Syndrome Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2457
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、93ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、脆弱X症候群のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ACT-01、AMO-01、ANAVEX-273、AUT-00206、ブリオスタチン-1、カンナビジオール、その他）、用途別市場規模（クリニック、病院、研究センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・脆弱X症候群の市場動向
・企業の競争状況、市場シェア
・脆弱X症候群の種類別市場規模（ACT-01、AMO-01、ANAVEX-273、AUT-00206、ブリオスタチン-1、カンナビジオール、その他）
・脆弱X症候群の用途別市場規模（クリニック、病院、研究センター）
・脆弱X症候群の北米市場規模2016-2027（アメリカ、カナダ）
・脆弱X症候群のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・脆弱X症候群のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・脆弱X症候群の中南米市場規模2016-2027（メキシコ、ブラジル）
・脆弱X症候群の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Aelis Farma SAS、Alcobra Ltd、AMO Pharma Limited、Confluence Pharmaceuticals LLC、Eli Lilly and Company、F. Hoffmann-La Roche Ltd.、Marinus Pharmaceuticals, Inc.、MI.TO. Technology S.r.L.、Neuren Pharmaceuticals Limited、Ovid Therapeutics Inc.、Sage Therapeutics, Inc.、Zynerba Pharmaceuticals, Inc.）
・結論

Market Analysis and Insights: Global Fragile X Syndrome Market
The global Fragile X Syndrome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Fragile X Syndrome market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Fragile X Syndrome market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Fragile X Syndrome market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Fragile X Syndrome market.

Global Fragile X Syndrome Scope and Market Size
Fragile X Syndrome market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Fragile X Syndrome market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
ACT-01
AMO-01
ANAVEX-273
AUT-00206
Bryostatin-1
Cannabidiol
Others

Segment by Application
Clinic
Hopital
Research Center

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Aelis Farma SAS
Alcobra Ltd
AMO Pharma Limited
Confluence Pharmaceuticals LLC
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Marinus Pharmaceuticals, Inc.
MI.TO. Technology S.r.L.
Neuren Pharmaceuticals Limited
Confluence Pharmaceuticals LLC

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Fragile X Syndrome Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 ACT-01
1.2.3 AMO-01
1.2.4 ANAVEX-273
1.2.5 AUT-00206
1.2.6 Bryostatin-1
1.2.7 Cannabidiol
1.2.8 Others
1.3 Market by Application
1.3.1 Global Fragile X Syndrome Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Clinic
1.3.3 Hopital
1.3.4 Research Center
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Fragile X Syndrome Market Perspective (2016-2027)
2.2 Fragile X Syndrome Growth Trends by Regions
2.2.1 Fragile X Syndrome Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Fragile X Syndrome Historic Market Share by Regions (2016-2021)
2.2.3 Fragile X Syndrome Forecasted Market Size by Regions (2022-2027)
2.3 Fragile X Syndrome Industry Dynamic
2.3.1 Fragile X Syndrome Market Trends
2.3.2 Fragile X Syndrome Market Drivers
2.3.3 Fragile X Syndrome Market Challenges
2.3.4 Fragile X Syndrome Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Fragile X Syndrome Players by Revenue
3.1.1 Global Top Fragile X Syndrome Players by Revenue (2016-2021)
3.1.2 Global Fragile X Syndrome Revenue Market Share by Players (2016-2021)
3.2 Global Fragile X Syndrome Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Fragile X Syndrome Revenue
3.4 Global Fragile X Syndrome Market Concentration Ratio
3.4.1 Global Fragile X Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Fragile X Syndrome Revenue in 2020
3.5 Fragile X Syndrome Key Players Head office and Area Served
3.6 Key Players Fragile X Syndrome Product Solution and Service
3.7 Date of Enter into Fragile X Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Fragile X Syndrome Breakdown Data by Type
4.1 Global Fragile X Syndrome Historic Market Size by Type (2016-2021)
4.2 Global Fragile X Syndrome Forecasted Market Size by Type (2022-2027)

5 Fragile X Syndrome Breakdown Data by Application
5.1 Global Fragile X Syndrome Historic Market Size by Application (2016-2021)
5.2 Global Fragile X Syndrome Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Fragile X Syndrome Market Size (2016-2027)
6.2 North America Fragile X Syndrome Market Size by Type
6.2.1 North America Fragile X Syndrome Market Size by Type (2016-2021)
6.2.2 North America Fragile X Syndrome Market Size by Type (2022-2027)
6.2.3 North America Fragile X Syndrome Market Size by Type (2016-2027)
6.3 North America Fragile X Syndrome Market Size by Application
6.3.1 North America Fragile X Syndrome Market Size by Application (2016-2021)
6.3.2 North America Fragile X Syndrome Market Size by Application (2022-2027)
6.3.3 North America Fragile X Syndrome Market Size by Application (2016-2027)
6.4 North America Fragile X Syndrome Market Size by Country
6.4.1 North America Fragile X Syndrome Market Size by Country (2016-2021)
6.4.2 North America Fragile X Syndrome Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Fragile X Syndrome Market Size (2016-2027)
7.2 Europe Fragile X Syndrome Market Size by Type
7.2.1 Europe Fragile X Syndrome Market Size by Type (2016-2021)
7.2.2 Europe Fragile X Syndrome Market Size by Type (2022-2027)
7.2.3 Europe Fragile X Syndrome Market Size by Type (2016-2027)
7.3 Europe Fragile X Syndrome Market Size by Application
7.3.1 Europe Fragile X Syndrome Market Size by Application (2016-2021)
7.3.2 Europe Fragile X Syndrome Market Size by Application (2022-2027)
7.3.3 Europe Fragile X Syndrome Market Size by Application (2016-2027)
7.4 Europe Fragile X Syndrome Market Size by Country
7.4.1 Europe Fragile X Syndrome Market Size by Country (2016-2021)
7.4.2 Europe Fragile X Syndrome Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Fragile X Syndrome Market Size (2016-2027)
8.2 Asia-Pacific Fragile X Syndrome Market Size by Type
8.2.1 Asia-Pacific Fragile X Syndrome Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Fragile X Syndrome Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Fragile X Syndrome Market Size by Type (2016-2027)
8.3 Asia-Pacific Fragile X Syndrome Market Size by Application
8.3.1 Asia-Pacific Fragile X Syndrome Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Fragile X Syndrome Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Fragile X Syndrome Market Size by Application (2016-2027)
8.4 Asia-Pacific Fragile X Syndrome Market Size by Region
8.4.1 Asia-Pacific Fragile X Syndrome Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Fragile X Syndrome Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Fragile X Syndrome Market Size (2016-2027)
9.2 Latin America Fragile X Syndrome Market Size by Type
9.2.1 Latin America Fragile X Syndrome Market Size by Type (2016-2021)
9.2.2 Latin America Fragile X Syndrome Market Size by Type (2022-2027)
9.2.3 Latin America Fragile X Syndrome Market Size by Type (2016-2027)
9.3 Latin America Fragile X Syndrome Market Size by Application
9.3.1 Latin America Fragile X Syndrome Market Size by Application (2016-2021)
9.3.2 Latin America Fragile X Syndrome Market Size by Application (2022-2027)
9.3.3 Latin America Fragile X Syndrome Market Size by Application (2016-2027)
9.4 Latin America Fragile X Syndrome Market Size by Country
9.4.1 Latin America Fragile X Syndrome Market Size by Country (2016-2021)
9.4.2 Latin America Fragile X Syndrome Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Fragile X Syndrome Market Size (2016-2027)
10.2 Middle East & Africa Fragile X Syndrome Market Size by Type
10.2.1 Middle East & Africa Fragile X Syndrome Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Fragile X Syndrome Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Fragile X Syndrome Market Size by Type (2016-2027)
10.3 Middle East & Africa Fragile X Syndrome Market Size by Application
10.3.1 Middle East & Africa Fragile X Syndrome Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Fragile X Syndrome Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Fragile X Syndrome Market Size by Application (2016-2027)
10.4 Middle East & Africa Fragile X Syndrome Market Size by Country
10.4.1 Middle East & Africa Fragile X Syndrome Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Fragile X Syndrome Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Aelis Farma SAS
11.1.1 Aelis Farma SAS Company Details
11.1.2 Aelis Farma SAS Business Overview
11.1.3 Aelis Farma SAS Fragile X Syndrome Introduction
11.1.4 Aelis Farma SAS Revenue in Fragile X Syndrome Business (2016-2021)
11.1.5 Aelis Farma SAS Recent Development
11.2 Alcobra Ltd
11.2.1 Alcobra Ltd Company Details
11.2.2 Alcobra Ltd Business Overview
11.2.3 Alcobra Ltd Fragile X Syndrome Introduction
11.2.4 Alcobra Ltd Revenue in Fragile X Syndrome Business (2016-2021)
11.2.5 Alcobra Ltd Recent Development
11.3 AMO Pharma Limited
11.3.1 AMO Pharma Limited Company Details
11.3.2 AMO Pharma Limited Business Overview
11.3.3 AMO Pharma Limited Fragile X Syndrome Introduction
11.3.4 AMO Pharma Limited Revenue in Fragile X Syndrome Business (2016-2021)
11.3.5 AMO Pharma Limited Recent Development
11.4 Confluence Pharmaceuticals LLC
11.4.1 Confluence Pharmaceuticals LLC Company Details
11.4.2 Confluence Pharmaceuticals LLC Business Overview
11.4.3 Confluence Pharmaceuticals LLC Fragile X Syndrome Introduction
11.4.4 Confluence Pharmaceuticals LLC Revenue in Fragile X Syndrome Business (2016-2021)
11.4.5 Confluence Pharmaceuticals LLC Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Details
11.5.2 Eli Lilly and Company Business Overview
11.5.3 Eli Lilly and Company Fragile X Syndrome Introduction
11.5.4 Eli Lilly and Company Revenue in Fragile X Syndrome Business (2016-2021)
11.5.5 Eli Lilly and Company Recent Development
11.6 F. Hoffmann-La Roche Ltd.
11.6.1 F. Hoffmann-La Roche Ltd. Company Details
11.6.2 F. Hoffmann-La Roche Ltd. Business Overview
11.6.3 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Introduction
11.6.4 F. Hoffmann-La Roche Ltd. Revenue in Fragile X Syndrome Business (2016-2021)
11.6.5 F. Hoffmann-La Roche Ltd. Recent Development
11.7 Marinus Pharmaceuticals, Inc.
11.7.1 Marinus Pharmaceuticals, Inc. Company Details
11.7.2 Marinus Pharmaceuticals, Inc. Business Overview
11.7.3 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Introduction
11.7.4 Marinus Pharmaceuticals, Inc. Revenue in Fragile X Syndrome Business (2016-2021)
11.7.5 Marinus Pharmaceuticals, Inc. Recent Development
11.8 MI.TO. Technology S.r.L.
11.8.1 MI.TO. Technology S.r.L. Company Details
11.8.2 MI.TO. Technology S.r.L. Business Overview
11.8.3 MI.TO. Technology S.r.L. Fragile X Syndrome Introduction
11.8.4 MI.TO. Technology S.r.L. Revenue in Fragile X Syndrome Business (2016-2021)
11.8.5 MI.TO. Technology S.r.L. Recent Development
11.9 Neuren Pharmaceuticals Limited
11.9.1 Neuren Pharmaceuticals Limited Company Details
11.9.2 Neuren Pharmaceuticals Limited Business Overview
11.9.3 Neuren Pharmaceuticals Limited Fragile X Syndrome Introduction
11.9.4 Neuren Pharmaceuticals Limited Revenue in Fragile X Syndrome Business (2016-2021)
11.9.5 Neuren Pharmaceuticals Limited Recent Development
11.10 Ovid Therapeutics Inc.
11.10.1 Ovid Therapeutics Inc. Company Details
11.10.2 Ovid Therapeutics Inc. Business Overview
11.10.3 Ovid Therapeutics Inc. Fragile X Syndrome Introduction
11.10.4 Ovid Therapeutics Inc. Revenue in Fragile X Syndrome Business (2016-2021)
11.10.5 Ovid Therapeutics Inc. Recent Development
11.11 Sage Therapeutics, Inc.
11.11.1 Sage Therapeutics, Inc. Company Details
11.11.2 Sage Therapeutics, Inc. Business Overview
11.11.3 Sage Therapeutics, Inc. Fragile X Syndrome Introduction
11.11.4 Sage Therapeutics, Inc. Revenue in Fragile X Syndrome Business (2016-2021)
11.11.5 Sage Therapeutics, Inc. Recent Development
11.12 Zynerba Pharmaceuticals, Inc.
11.12.1 Zynerba Pharmaceuticals, Inc. Company Details
11.12.2 Zynerba Pharmaceuticals, Inc. Business Overview
11.12.3 Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Introduction
11.12.4 Zynerba Pharmaceuticals, Inc. Revenue in Fragile X Syndrome Business (2016-2021)
11.12.5 Zynerba Pharmaceuticals, Inc. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Fragile X Syndrome Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of ACT-01
Table 3. Key Players of AMO-01
Table 4. Key Players of ANAVEX-273
Table 5. Key Players of AUT-00206
Table 6. Key Players of Bryostatin-1
Table 7. Key Players of Cannabidiol
Table 8. Key Players of Others
Table 9. Global Fragile X Syndrome Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Fragile X Syndrome Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Fragile X Syndrome Market Size by Regions (2016-2021) & (US$ Million)
Table 12. Global Fragile X Syndrome Market Share by Regions (2016-2021)
Table 13. Global Fragile X Syndrome Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 14. Global Fragile X Syndrome Market Share by Regions (2022-2027)
Table 15. Fragile X Syndrome Market Trends
Table 16. Fragile X Syndrome Market Drivers
Table 17. Fragile X Syndrome Market Challenges
Table 18. Fragile X Syndrome Market Restraints
Table 19. Global Fragile X Syndrome Revenue by Players (2016-2021) & (US$ Million)
Table 20. Global Fragile X Syndrome Market Share by Players (2016-2021)
Table 21. Global Top Fragile X Syndrome Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fragile X Syndrome as of 2020)
Table 22. Ranking of Global Top Fragile X Syndrome Companies by Revenue (US$ Million) in 2020
Table 23. Global 5 Largest Players Market Share by Fragile X Syndrome Revenue (CR5 and HHI) & (2016-2021)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Fragile X Syndrome Product Solution and Service
Table 26. Date of Enter into Fragile X Syndrome Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Fragile X Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 29. Global Fragile X Syndrome Revenue Market Share by Type (2016-2021)
Table 30. Global Fragile X Syndrome Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 31. Global Fragile X Syndrome Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 32. Global Fragile X Syndrome Market Size Share by Application (2016-2021) & (US$ Million)
Table 33. Global Fragile X Syndrome Revenue Market Share by Application (2016-2021)
Table 34. Global Fragile X Syndrome Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 35. Global Fragile X Syndrome Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 36. North America Fragile X Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 37. North America Fragile X Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 38. North America Fragile X Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 39. North America Fragile X Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 40. North America Fragile X Syndrome Market Size by Country (2016-2021) & (US$ Million)
Table 41. North America Fragile X Syndrome Market Size by Country (2022-2027) & (US$ Million)
Table 42. Europe Fragile X Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 43. Europe Fragile X Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 44. Europe Fragile X Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 45. Europe Fragile X Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 46. Europe Fragile X Syndrome Market Size by Country (2016-2021) & (US$ Million)
Table 47. Europe Fragile X Syndrome Market Size by Country (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Fragile X Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 49. Asia-Pacific Fragile X Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Fragile X Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 51. Asia-Pacific Fragile X Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 52. Asia-Pacific Fragile X Syndrome Market Size by Region (2016-2021) & (US$ Million)
Table 53. Asia-Pacific Fragile X Syndrome Market Size by Region (2022-2027) & (US$ Million)
Table 54. Latin America Fragile X Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 55. Latin America Fragile X Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 56. Latin America Fragile X Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 57. Latin America Fragile X Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 58. Latin America Fragile X Syndrome Market Size by Country (2016-2021) & (US$ Million)
Table 59. Latin America Fragile X Syndrome Market Size by Country (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Fragile X Syndrome Market Size by Type (2016-2021) (US$ Million)
Table 61. Middle East & Africa Fragile X Syndrome Market Size by Type (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Fragile X Syndrome Market Size by Application (2016-2021) (US$ Million)
Table 63. Middle East & Africa Fragile X Syndrome Market Size by Application (2022-2027) & (US$ Million)
Table 64. Middle East & Africa Fragile X Syndrome Market Size by Country (2016-2021) & (US$ Million)
Table 65. Middle East & Africa Fragile X Syndrome Market Size by Country (2022-2027) & (US$ Million)
Table 66. Aelis Farma SAS Company Details
Table 67. Aelis Farma SAS Business Overview
Table 68. Aelis Farma SAS Fragile X Syndrome Product
Table 69. Aelis Farma SAS Revenue in Fragile X Syndrome Business (2016-2021) & (US$ Million)
Table 70. Aelis Farma SAS Recent Development
Table 71. Alcobra Ltd Company Details
Table 72. Alcobra Ltd Business Overview
Table 73. Alcobra Ltd Fragile X Syndrome Product
Table 74. Alcobra Ltd Revenue in Fragile X Syndrome Business (2016-2021) & (US$ Million)
Table 75. Alcobra Ltd Recent Development
Table 76. AMO Pharma Limited Company Details
Table 77. AMO Pharma Limited Business Overview
Table 78. AMO Pharma Limited Fragile X Syndrome Product
Table 79. AMO Pharma Limited Revenue in Fragile X Syndrome Business (2016-2021) & (US$ Million)
Table 80. AMO Pharma Limited Recent Development
Table 81. Confluence Pharmaceuticals LLC Company Details
Table 82. Confluence Pharmaceuticals LLC Business Overview
Table 83. Confluence Pharmaceuticals LLC Fragile X Syndrome Product
Table 84. Confluence Pharmaceuticals LLC Revenue in Fragile X Syndrome Business (2016-2021) & (US$ Million)
Table 85. Confluence Pharmaceuticals LLC Recent Development
Table 86. Eli Lilly and Company Company Details
Table 87. Eli Lilly and Company Business Overview
Table 88. Eli Lilly and Company Fragile X Syndrome Product
Table 89. Eli Lilly and Company Revenue in Fragile X Syndrome Business (2016-2021) & (US$ Million)
Table 90. Eli Lilly and Company Recent Development
Table 91. F. Hoffmann-La Roche Ltd. Company Details
Table 92. F. Hoffmann-La Roche Ltd. Business Overview
Table 93. F. Hoffmann-La Roche Ltd. Fragile X Syndrome Product
Table 94. F. Hoffmann-La Roche Ltd. Revenue in Fragile X Syndrome Business (2016-2021) & (US$ Million)
Table 95. F. Hoffmann-La Roche Ltd. Recent Development
Table 96. Marinus Pharmaceuticals, Inc. Company Details
Table 97. Marinus Pharmaceuticals, Inc. Business Overview
Table 98. Marinus Pharmaceuticals, Inc. Fragile X Syndrome Product
Table 99. Marinus Pharmaceuticals, Inc. Revenue in Fragile X Syndrome Business (2016-2021) & (US$ Million)
Table 100. Marinus Pharmaceuticals, Inc. Recent Development
Table 101. MI.TO. Technology S.r.L. Company Details
Table 102. MI.TO. Technology S.r.L. Business Overview
Table 103. MI.TO. Technology S.r.L. Revenue in Fragile X Syndrome Business (2016-2021) & (US$ Million)
Table 104. MI.TO. Technology S.r.L. Recent Development
Table 105. Neuren Pharmaceuticals Limited Company Details
Table 106. Neuren Pharmaceuticals Limited Business Overview
Table 107. Neuren Pharmaceuticals Limited Fragile X Syndrome Product
Table 108. Neuren Pharmaceuticals Limited Revenue in Fragile X Syndrome Business (2016-2021) & (US$ Million)
Table 109. Neuren Pharmaceuticals Limited Recent Development
Table 110. Ovid Therapeutics Inc. Company Details
Table 111. Ovid Therapeutics Inc. Business Overview
Table 112. Ovid Therapeutics Inc. Fragile X Syndrome Product
Table 113. Ovid Therapeutics Inc. Revenue in Fragile X Syndrome Business (2016-2021) & (US$ Million)
Table 114. Ovid Therapeutics Inc. Recent Development
Table 115. Sage Therapeutics, Inc. Company Details
Table 116. Sage Therapeutics, Inc. Business Overview
Table 117. Sage Therapeutics, Inc. Fragile X Syndrome Product
Table 118. Sage Therapeutics, Inc. Revenue in Fragile X Syndrome Business (2016-2021) & (US$ Million)
Table 119. Sage Therapeutics, Inc. Recent Development
Table 120. Zynerba Pharmaceuticals, Inc. Company Details
Table 121. Zynerba Pharmaceuticals, Inc. Business Overview
Table 122. Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Product
Table 123. Zynerba Pharmaceuticals, Inc. Revenue in Fragile X Syndrome Business (2016-2021) & (US$ Million)
Table 124. Zynerba Pharmaceuticals, Inc. Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Fragile X Syndrome Market Share by Type: 2020 VS 2027
Figure 2. ACT-01 Features
Figure 3. AMO-01 Features
Figure 4. ANAVEX-273 Features
Figure 5. AUT-00206 Features
Figure 6. Bryostatin-1 Features
Figure 7. Cannabidiol Features
Figure 8. Others Features
Figure 9. Global Fragile X Syndrome Market Share by Application: 2020 VS 2027
Figure 10. Clinic Case Studies
Figure 11. Hopital Case Studies
Figure 12. Research Center Case Studies
Figure 13. Fragile X Syndrome Report Years Considered
Figure 14. Global Fragile X Syndrome Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Fragile X Syndrome Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Fragile X Syndrome Market Share by Regions: 2020 VS 2027
Figure 17. Global Fragile X Syndrome Market Share by Regions (2022-2027)
Figure 18. Global Fragile X Syndrome Market Share by Players in 2020
Figure 19. Global Top Fragile X Syndrome Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fragile X Syndrome as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Fragile X Syndrome Revenue in 2020
Figure 21. Global Fragile X Syndrome Revenue Market Share by Type (2016-2021)
Figure 22. Global Fragile X Syndrome Revenue Market Share by Type (2022-2027)
Figure 23. North America Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Fragile X Syndrome Market Share by Type (2016-2027)
Figure 25. North America Fragile X Syndrome Market Share by Application (2016-2027)
Figure 26. North America Fragile X Syndrome Market Share by Country (2016-2027)
Figure 27. United States Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Fragile X Syndrome Market Share by Type (2016-2027)
Figure 31. Europe Fragile X Syndrome Market Share by Application (2016-2027)
Figure 32. Europe Fragile X Syndrome Market Share by Country (2016-2027)
Figure 33. Germany Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Fragile X Syndrome Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Fragile X Syndrome Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Fragile X Syndrome Market Share by Region (2016-2027)
Figure 43. China Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Fragile X Syndrome Market Share by Type (2016-2027)
Figure 51. Latin America Fragile X Syndrome Market Share by Application (2016-2027)
Figure 52. Latin America Fragile X Syndrome Market Share by Country (2016-2027)
Figure 53. Mexico Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Fragile X Syndrome Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Fragile X Syndrome Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Fragile X Syndrome Market Share by Country (2016-2027)
Figure 59. Turkey Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Fragile X Syndrome Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Aelis Farma SAS Revenue Growth Rate in Fragile X Syndrome Business (2016-2021)
Figure 63. Alcobra Ltd Revenue Growth Rate in Fragile X Syndrome Business (2016-2021)
Figure 64. AMO Pharma Limited Revenue Growth Rate in Fragile X Syndrome Business (2016-2021)
Figure 65. Confluence Pharmaceuticals LLC Revenue Growth Rate in Fragile X Syndrome Business (2016-2021)
Figure 66. Eli Lilly and Company Revenue Growth Rate in Fragile X Syndrome Business (2016-2021)
Figure 67. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Fragile X Syndrome Business (2016-2021)
Figure 68. Marinus Pharmaceuticals, Inc. Revenue Growth Rate in Fragile X Syndrome Business (2016-2021)
Figure 69. MI.TO. Technology S.r.L. Revenue Growth Rate in Fragile X Syndrome Business (2016-2021)
Figure 70. Neuren Pharmaceuticals Limited Revenue Growth Rate in Fragile X Syndrome Business (2016-2021)
Figure 71. Ovid Therapeutics Inc. Revenue Growth Rate in Fragile X Syndrome Business (2016-2021)
Figure 72. Sage Therapeutics, Inc. Revenue Growth Rate in Fragile X Syndrome Business (2016-2021)
Figure 73. Zynerba Pharmaceuticals, Inc. Revenue Growth Rate in Fragile X Syndrome Business (2016-2021)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed

以下、関連資料のご紹介

世界の脆弱X症候群市場規模・現状・予測（2021年-2027年）

Global Fragile X Syndrome Market Size, Status and Forecast 2021-2027
QYR2104Z2457 2021年4月 93Pages
QYResearch社発行の本調査資料では、脆弱X症候群のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ACT-01、AMO-01、ANAVEX-273、AUT-00206、ブリオスタチン-1、カンナビジオール、その他）、用途別市場規模（クリニ...

世界の脆弱X症候群遺伝子検査市場規模・現状・予測（2021年-2027年）

Global Fragile X Syndrome Genetic Testing Market Size, Status and Forecast 2021-2027
QYR2104Z2456 2021年4月 97Pages
QYResearch社発行の本調査資料では、脆弱X症候群遺伝子検査のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（遺伝子スクリーニング、生殖遺伝子検査、診断検査、遺伝子保因者検査、症状前検査）、用途別市場規模（病院、クリニック、診断センター）、...

世界のドラベ症候群治療市場規模・現状・予測（2021年-2027年）

Global Dravet Syndrome Thereapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z1960 2021年4月 91Pages
QYResearch社発行の本調査資料では、ドラベ症候群治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（BIS-001、カンナビジオール、CUR-1916、SAGE-217、その他）、用途別市場規模（クリニック、病院、その他）、主要地域別市...

世界のドラベ症候群治療市場規模・現状・予測（2021年-2027年）

世界の過敏性腸症候群治療市場規模・現状・予測（2021年-2027年）

Global Irritable Bowel Syndrome Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z3283 2021年4月 95Pages
QYResearch社発行の本調査資料では、過敏性腸症候群治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（便秘過敏性腸症候群、下痢過敏性腸症候群、便秘・下痢過敏性腸症候群）、用途別市場規模（病院、クリニック、在宅ケア）、主要地域別市場規模（...

世界の過敏性腸症候群治療市場規模・現状・予測（2021年-2027年）

世界のドラベ症候群治療市場規模・現状・予測（2021年-2027年）

Global Dravet Syndrome Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z1961 2021年4月 92Pages
QYResearch社発行の本調査資料では、ドラベ症候群治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（第一世代薬品（FGD）、第二世代薬品（SGD）、第三世代薬品（TGD））、用途別市場規模（病院薬局、小売薬局、Eコマース、その他）、主要...

世界の腫瘍崩壊症候群市場規模・現状・予測（2021年-2027年）

Global Tumor Lysis Syndrome Market Size, Status and Forecast 2021-2027
QYR2104Z5758 2021年4月 92Pages
QYResearch社発行の本調査資料では、腫瘍崩壊症候群のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アロプリノール、フェブキソスタット、ラスブリカーゼ、その他）、用途別市場規模（病院薬局、小売薬局、その他）、主要地域別市場規模（北米、アメ...

世界のチャーグストラウス症候群市場規模・現状・予測（2021年-2027年）

Global Churg Strauss Syndrome Market Size, Status and Forecast 2021-2027
QYR2104Z1332 2021年4月 99Pages
QYResearch社発行の本調査資料では、チャーグストラウス症候群のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（生物製剤、免疫グロブリン、ワクチン、ステロイド、その他）、用途別市場規模（研究所、病院、クリニック、その他）、主要地域別市場規模...

世界の短腸症候群（SBS）市場規模・現状・予測（2021年-2027年）

Global Short Bowel Syndrome (SBS) Market Size, Status and Forecast 2021-2027
QYR2104Z5225 2021年4月 96Pages
QYResearch社発行の本調査資料では、短腸症候群（SBS）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（経口、非経口）、用途別市場規模（病院、診療所、小売薬局）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、...

世界の脆弱X症候群市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Fragile X Syndrome Market The global Fragile X Syndrome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report makes…
世界の脆弱X症候群遺伝子検査市場規模・現状・予測（2021年-2027年） Fragile X Syndrome Gene Test, designed to detect the Fragile X Syndrome gene Market Analysis and Insights: Global Fragile X Syndrome Genetic Testing Market The global Fragile X Syndrome Genetic Testing market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR o…
世界のレット症候群治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Rett Syndrome Therapeutics Market The global Rett Syndrome Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, …
世界のドラベ症候群治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Dravet Syndrome Thereapeutics Market The global Dravet Syndrome Thereapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integ…
世界のドラベ症候群治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Dravet Syndrome Thereapeutics Market The global Dravet Syndrome Thereapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integ…